Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Friday, April 8, 2022 BiopharmaWatch Research 1 min read
Key Takeaway: Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Price reaction · baseline $37.42 (2022-04-07 close) · hit after-hours · clean, no other KYMR news in the window
day 0 close · peak
-4.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
4.3%
average across 7 past catalysts
Cash runway
~83 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Atopic Dermatitis
Full Press Release Details
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022.